300146:SZSEBy-health Co., Ltd. Class A Analysis

Byhealth's shares are trading at CNY 11.73, which sits below the 20‑day SMA of 11.85 and the 200‑day SMA of 11.997, indicating short‑term weakness. The price is hovering just above the calculated support level of 11.31 and well under the resistance at 12.56, suggesting a tight range bound. Technical momentum is mixed, with an RSI of 44 (neutral) but a bullish MACD crossover (line above signal) producing a small positive histogram. Trading volume has been on a decreasing trend, while 30‑day volatility remains elevated at 19.6 %, reflecting modest price swings. The stock’s beta of 0.22 points to low sensitivity to broader market moves, which tempers systematic risk. Valuation metrics are striking: the DCF‑derived fair value of 52.9 implies roughly a 42 % upside from current levels. A dividend yield of 3 % with a 90 % payout ratio is supported by ample cash (5.65 bn CNY) and strong free cash flow.
Fundamentally, Byhealth delivered a robust 23.5 % revenue growth year‑over‑year, underpinned by a gross margin of 66 % and operating margin of 12 %. Profitability remains solid at an EPS of 0.40 and a forward EPS of 0.55, translating to a forward P/E of 21.5, well below the historical trailing P/E of 29.3. The balance sheet is healthy, with a low debt‑to‑equity of 9.5 % and a cash‑rich position that comfortably covers the modest debt load. Analyst consensus (5 analysts) rates the stock as a “buy,” with mean target price of 16.63 and median of 14.56, reinforcing the upside narrative. Operating in the consumer‑defensive packaged‑foods segment provides stability, though regulatory scrutiny of health supplements and concentration in China introduce medium‑level risks. Overall, the combination of undervaluation, strong cash generation, and attractive dividend makes Byhealth a compelling addition for investors seeking both growth and income.